Patriot Financial Group Insurance Agency LLC grew its position in Bristol-Myers Squibb Company (NYSE:BMY) by 7.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,768 shares of the biopharmaceutical company’s stock after buying an additional 574 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Bristol-Myers Squibb were worth $490,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Ray Gerald L & Associates Ltd. boosted its holdings in shares of Bristol-Myers Squibb by 1.5% in the second quarter. Ray Gerald L & Associates Ltd. now owns 171,655 shares of the biopharmaceutical company’s stock worth $9,564,000 after buying an additional 2,530 shares during the period. Boulegeris Investments Inc. boosted its holdings in shares of Bristol-Myers Squibb by 3.2% in the second quarter. Boulegeris Investments Inc. now owns 46,338 shares of the biopharmaceutical company’s stock worth $2,582,000 after buying an additional 1,430 shares during the period. QCI Asset Management Inc. NY boosted its holdings in shares of Bristol-Myers Squibb by 6.5% in the second quarter. QCI Asset Management Inc. NY now owns 231,766 shares of the biopharmaceutical company’s stock worth $12,914,000 after buying an additional 14,110 shares during the period. Lipe & Dalton boosted its holdings in shares of Bristol-Myers Squibb by 8.1% in the second quarter. Lipe & Dalton now owns 67,209 shares of the biopharmaceutical company’s stock worth $3,745,000 after buying an additional 5,030 shares during the period. Finally, Brighton Jones LLC boosted its holdings in shares of Bristol-Myers Squibb by 18.7% in the second quarter. Brighton Jones LLC now owns 16,134 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 2,538 shares during the period. Institutional investors own 69.51% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.07 on Thursday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a market cap of $100,247.88, a P/E ratio of 20.69, a PEG ratio of 2.42 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the business earned $0.77 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. sell-side analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (BMY) Holdings Lifted by Patriot Financial Group Insurance Agency LLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/16/bristol-myers-squibb-company-bmy-holdings-lifted-by-patriot-financial-group-insurance-agency-llc.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.

BMY has been the subject of a number of research analyst reports. Credit Suisse Group reissued a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Cowen and Company reissued a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group LLC increased their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Leerink Swann increased their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $64.93.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.